Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4903893 | 1.00 | PGR (0.48) | PGRCYP2C19 | |
| SCHEMBL4902172 | 0.89 | PGR (0.48) | PGRCYP2C19 | |
| SCHEMBL4904296 | 0.89 | PGR (0.50) | PGRCYP2C19 | |
| SCHEMBL4902181 | 0.89 | PGR (0.48) | PGRCYP2C19 | |
| SCHEMBL4896904 | 0.87 | MAOA (0.38) | PGRCYP2C19 | |
| SCHEMBL4896895 | 0.87 | MAOA (0.38) | PGRCYP2C19 | |
| SCHEMBL4894270 | 0.84 | PGR (0.49) | PGRCYP2C19 | |
| SCHEMBL4894275 | 0.84 | PGR (0.49) | PGRCYP2C19 | |
| SCHEMBL3060299 | 0.80 | AR (0.54) | PGR | |
| SCHEMBL4896538 | 0.80 | AR (0.54) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | US | claimed |
| EP-1747193-A1 | BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY | Pfizer Products Incorporated (US) | 2007-01-31 | — | — | EP | claimed |
| WO-2005108351-A1 | BENZONITRILE DERIVATIVES TO TREAT MUSCULOSKELETAL FRAILTY | PFIZER PRODUCTS INC. (US) | 2005-11-17 | — | — | WO | claimed |
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | PFIZER PRODUCTS INC. (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2006024931-A2 | THERAPEUTIC COMBINATIONS COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND A SELECTIVE ANDROGEN RECEPTOR MODULATOR | PFIZER PRODUCTS INC. (US) | 2006-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045504-A1 | Benzonitrile Derivatives to Treat Musculoskeletal Frailty | TNNC1, TNNI3, TNNT2 | PGR 1921/4885CYP2C19 2549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.